Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012440 | 1.00 | TP53 (0.45) | TP53GPR119MGLLHPGDSPDE4B | |
| SCHEMBL13230102 | 0.85 | TP53 (0.48) | TP53GPR119SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1015101 | 0.82 | SFRP1 (0.46) | TP53GPR119PDE4B | |
| SCHEMBL1015103 | 0.82 | SFRP1 (0.46) | TP53GPR119PDE4B | |
| SCHEMBL3547383 | 0.80 | SMN1; SMN2 (0.53) | TP53GPR119SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2473362 | 0.80 | PDE4B (0.50) | GPR119HPGDSPDE4BKDM4EMAPT | |
| SCHEMBL2229006 | 0.79 | GPR119 (0.42) | TP53GPR119MGLLHPGDS | |
| SCHEMBL19404908 | 0.79 | SMN1; SMN2 (0.54) | TP53GPR119PDE4BSMN1; SMN2BRD3 | |
| SCHEMBL31158869 | 0.79 | PDE4B (0.57) | TP53GPR119HPGDSPDE4BSMN1; SMN2 | |
| SCHEMBL20531395 | 0.79 | PDE4B (0.57) | TP53GPR119HPGDSPDE4BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | TP53 4375/4885GPR119 138/4885MGLL 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.